Paraoxonase-1 and myeloperoxidase correlate with vascular biomarkers                     in overweight patients with newly diagnosed untreated                     hyperlipidaemia

Szentpéteri, Anita; Zsíros, Noémi; Varga, V.; Lőrincz, Hajnalka; Katkó, Mónika; Serés, I.; Fülöp, Péter; Paragh, György; Harangi, Mariann

doi:10.1024/0301-1526/a000643

Cited by 8 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma, serum, and leukocyte MPO levels have been associated with coronary artery disease [25] ; incident risk of myocardial infarction, death, and need for revascularization [26,27] . In a previous study we found significantly elevated MPO levels in overweight hyperlipidemic patients with or without cardiovascular complications [28] . In the present study we also found significantly higher MPO levels in dyslipidemic patients without any vascular complications compared to healthy subjects.…”

Section: Discussionmentioning

confidence: 99%

HDL subfraction distribution and HDL function in untreated dyslipidemic patients

Harangi¹,

Szentpéteri²,

Nádró³

et al. 2017

Self Cite

View full text Add to dashboard Cite

Aim:The protective role of high-density lipoprotein (HDL) against atherosclerosis is well known. However, both structural and functional changes of the HDL particles may affect its protective efficacy. Increased levels of HDL-associated myeloperoxidase (MPO) and decreased HDL-linked paraoxonase-1 (PON1) activity have been reported in dyslipidemic patients. Some changes in HDL subfraction distributions were also studied previously, but data on structural and functional changes in dyslipidemia are not complete. Therefore, the authors aimed to evaluate these qualitative and quantitative markers of HDL in dyslipidemic patients and healthy control subjects. Methods: Anthropometric parameters, serum levels of lipoproteins and MPO, as well as PON1 activities were investigated in 81 untreated dyslipidemic patients and in 32 healthy gender-matched controls. Additionally, HDL subfractions were detected by an electrophoretic method on polyacrylamide gel (Lipoprint). Results: Significantly higher glucose, hemoglobin A1c, total cholesterol, low-density lipoprotein-cholesterol, triglyceride, lipoprotein(a), apolipoprotein B, C-reactive protein, and MPO levels were found in patients compared to the healthy subjects. There were no significant differences in PON1 paraoxonase and arylesterase activities between the two study groups, but MPO/PON1 ratio was significantly higher in patients. There was a shift towards the smaller HDL subfractions, but only the intermediate HDL ratio was significantly lower in patients compared to controls. Conclusion:The results highlight the importance of HDL-associated pro-and antioxidant enzymes suggesting the possible clinical benefit of MPO/PON1 calculation and confirm that quantification of HDL-C level alone provides limited data regarding HDL's cardioprotective effect. Calculation of MPO/PON1 ratio may be a useful cardiovascular marker in dyslipidemia. Key words:High-density lipoprotein, subfraction, paraoxonase, myeloperoxidase, dyslipidemia ABSTRACTArticle history:

show abstract

Section: Discussionmentioning

confidence: 99%

HDL subfraction distribution and HDL function in untreated dyslipidemic patients

Harangi¹,

Szentpéteri²,

Nádró³

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Az ADMA, az adhéziós molekulák, oxidált LDL szinteket, valamint a myeloperoxidáz koncentrációt és a PON1 aktivitást mértük. Azt találtuk, hogy a myeloperoxidáz szignifikánsan fokozódott, a PON1 aktivitás pedig csökkent (Szentpéteri et al, 2017). A HDL, a myeloperoxidáz és a PON1 egy úgynevezett hármas komplexet hoz létre és ennek az egyensúlya határozza meg, hogy a HDL antiatherogén vagy atherosclerosist elősegítő-e.…”

Section: Elhízás Vesebetegség Vesetranszplantáció Autoimmun Betegsége...unclassified

Primer és szekunder hyperlipoproteinaemiák jelentősége fokozott kardiovaszkuláris kockázatú betegben

Paragh

2023

Debr. szle.

View full text Add to dashboard Cite

show abstract

“…Full blood count including hemoglobin (hgb), hematocrit (htc), white blood cells (WBC), red blood cells (RBC), platelets (PLT), as well as neutrophil and lymphocyte absolute counts were determined by routine laboratory analyses at all time points. PON1 PON activity (U/L) was determined on a microtiter plate by a kinetic, semiautomated method using paraoxon (O,O-diethyl-O-p-nitrophenyl-phosphate, Sigma Aldrich) as a substrate [53,54]. PON1 ARE activity (U/L) was assayed with a phenylacetate substrate (Sigma Aldrich Brand, Merck, Darmstadt, Germany) and the hydrolysis of phenylacetate was monitored at 270 nm [34,53].…”

Section: Laboratory Measurementsmentioning

confidence: 99%

Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Cardiovascular (CV) morbidity, mortality, and metabolic syndrome are associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Here, lipids and other metabolic markers in relation to vascular function and clinical markers were evaluated in RA and AS patients undergoing one-year anti-TNF therapy. Patients and methods: Fifty-three patients including 36 RA patients treated with either etanercept (ETN) or certolizumab pegol (CZP) and 17 AS patients treated with ETN were included in a 12-month follow-up study. Various lipids, paraoxonase (PON) and arylesterase (ARE) activities, myeloperoxidase (MPO) and adipokine levels were determined overtime. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT), and arterial pulse-wave velocity (PWV) in all patients. All assessments were performed at baseline and 6 and 12 months after treatment initiation. Results: Anti-TNF therapy decreased ARE activity, MPO, adiponectin, and chemerin levels after 12 months (p < 0.05). Lipids, PON activity, and leptin remained unchanged. Regression analyses suggested variable associations of IMT, PWV, and FMD with ARE, MPO, leptin, and lipids (p < 0.05). On the other hand, these metabolic parameters were significantly associated with disease duration, CV history, CRP, obesity, PWV, and IMT (p < 0.05). One-year anti-TNF treatment together with baseline leptin (p = 0.039) or CRP (p = 0.016) levels determined 12 months of lipid changes overtime. TNF inhibition together with baseline disease activity determined ARE activity changes (p = 0.046). Anti-TNF therapy and baseline chemerin levels determined IMT changes overtime (p = 0.003). Conclusions: Assessment of various metabolic parameters together with disease activity, CRP, and ultrasound-based techniques may exert additional value in determining CV burden and in monitoring the effects of biologics on preclinical vascular pathophysiology.

show abstract

Paraoxonase-1 and myeloperoxidase correlate with vascular biomarkers in overweight patients with newly diagnosed untreated hyperlipidaemia

Cited by 8 publications

References 26 publications

HDL subfraction distribution and HDL function in untreated dyslipidemic patients

HDL subfraction distribution and HDL function in untreated dyslipidemic patients

Primer és szekunder hyperlipoproteinaemiák jelentősége fokozott kardiovaszkuláris kockázatú betegben

Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology

Contact Info

Product

Resources

About